Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Apr;32(4):637-8.
doi: 10.3174/ajnr.A2593. Epub 2011 Mar 24.

Tositumomab and iodine I 131 tositumomab (Bexaar)

A Srinivasan  1 , S K Mukherji
Affiliations
Review

Tositumomab and iodine I 131 tositumomab (Bexaar)

A Srinivasan et al. AJNR Am J Neuroradiol. 2011 Apr.

Abstract

Tositumomab and iodine I 131 tositumomab (Bexaar) therapeutic regimen targets monoclonal antibodies against the CD20 antigen expressed in non-Hodgkin lymphoma. This article reviews the mechanism of action and clinical indications for this regimen.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
Contrast-enhanced CT scans at the level of the cricoid cartilage (A) and hyoid bone (B) in a 56-year-old male patient with rituximab-refractory non-Hodgkins lymphoma demonstrate enlarged level III/IV and level II lymph nodes (arrows).
Fig 2.
Fig 2.
A and B, Subsequent to Bexaar therapeutic regimen, the follow-up contrast-enhanced CT images show significant reduction in the size of these lymph nodes (arrows).
See this image and copyright information in PMC

References

    1. Rutar FJ, Augustine SC, Kaminski MS, et al. . Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members. Clin Lymphoma 2001;2:164–72 - PubMed
    1. Kaminski MS, Zelenetz AD, Press OW, et al. . Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918–28 - PubMed
    1. Kaminski MS, Estes J, Zasadny KR, et al. . Radioimmunotherapy with iodine (131) I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259–66 - PubMed
    1. Davies AJ. A review of tositumomab and I (131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma. Expert Opin Biol Ther 2005;5:577–88 - PubMed
    1. Kaminski MS, Tuck M, Estes J, et al. . 131 I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441–49 - PubMed

MeSH terms

LinkOut - more resources